| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5681502 | Medicine - Programa de Formación Médica Continuada Acreditado | 2017 | 11 Pages |
Abstract
The course of the disease is poor if left untreated. Early treatment prevents structural progression. Some patients respond to traditional therapies with DMARDs (mostly methotrexate) and avoid further damage, but in many cases biological drugs are required, such as anti-TNF/anti-interleukin, or even anti-CD20, that have played an undisputed role in this disease.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
A. Turrión Nieves, R. MartÃn Holguera, A. Pérez Gómez, M. Álvarez de Mon-Soto,